Related Experiment Video

Updated: May 4, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors

Meghna Das Thakur1, Darrin D Stuart

  • 1Authors' Affiliation: Novartis Institutes for Biomedical Research, Emeryville, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 20, 2013
PubMed

Insights

Targeting the RAS-RAF-MEK-ERK pathway with inhibitors shows promise in melanoma treatment. Understanding drug resistance is key to improving patient outcomes and developing new combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RAS-RAF-MEK-ERK pathway is crucial for tumor cell proliferation, survival, and metastasis.
  • Oncogenic mutations in RAS and BRAF are common, making this pathway a key target for cancer drug development.

Purpose of the Study:

  • To review the significance of the RAS-RAF-MEK-ERK pathway in cancer.
  • To discuss the therapeutic implications of targeting this pathway, particularly in melanoma.
  • To highlight the importance of understanding drug response and resistance.

Main Methods:

  • Literature review of studies on the RAS-RAF-MEK-ERK pathway and targeted therapies.
  • Analysis of clinical trial data for BRAF and MEK inhibitors in melanoma.
  • Discussion of emerging strategies for combination therapies and dosing regimens.

Main Results:

  • BRAF and MEK inhibitors have demonstrated success in extending survival for patients with BRAF(V600E/K)-mutant melanoma.
  • While not curative, these agents offer significant clinical benefit and insights into treatment resistance.
  • Understanding drug response mechanisms is crucial for optimizing treatment strategies.

Conclusions:

  • Targeting the RAS-RAF-MEK-ERK pathway is a validated therapeutic strategy in oncology, especially for melanoma.
  • Further research into drug resistance and combination therapies is essential for improving patient outcomes.
  • Insights gained from current therapies pave the way for novel treatment approaches.

More Related Videos

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

12.5K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.9K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K